Effect of adding PCSK9 inhibitors to lipid-lowering interventions on arterial stiffness: A systematic review and meta-analysis.
PCSK9 inhibitors
adults
arterial stiffness
lipid‐lowering interventions
pulse wave velocity
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
revised:
10
06
2024
received:
31
03
2024
accepted:
13
06
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
20
7
2024
Statut:
aheadofprint
Résumé
Atherosclerosis, a leading cause of mortality, necessitates effective management of hypercholesterolemia, specifically elevated low-density lipoprotein cholesterol (LDL-C). The emergence of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has revolutionised lipid-lowering. PCSK9i demonstrates substantial LDL-C reduction and cardiovascular benefits, particularly in statin-intolerant or nonresponsive individuals. However, the potential pleiotropic effects of PCSK9i, especially on arterial stiffness, remain a subject of investigation. This systematic review and meta-analysis seek to provide a nuanced understanding of the potential pleiotropic effects of PCSK9i, specifically on arterial health. The primary objective was to analyse the influence of PCSK9i on arterial stiffness, extending beyond traditional lipid-lowering metrics and contributing to a more comprehensive approach to cardiovascular risk reduction. A systematic search was conducted across major databases, clinical trial registries and grey literature. Inclusion criteria comprised adults in prospective cohort studies undergoing PCSK9i augmentation in lipid-lowering therapy, with a focus on arterial stiffness measured by pulse wave velocity (PWv). Random-effects meta-analyses, sensitivity analyses and meta-regression models were employed to assess the pooled effect of adding PCSK9i to lipid-lowering interventions on arterial stiffness. Five studies (158 participants) met the inclusion criteria, demonstrating a significant reduction in PWv (mean difference: -2.61 m/s [95% CI: -3.70, -1.52]; ES: -1.62 [95% CI: -2.53, -.71]) upon adding PCSK9i to lipid-lowering interventions. Subgroup analysis and meta-regression models suggested potential sex-based and baseline PWv-dependent variations, emphasising patient-specific characteristics. The meta-analysis provides robust evidence that adding PCSK9i to lipid-lowering interventions significantly improves arterial stiffness, indicating broader vascular benefits beyond LDL-C reduction.
Sections du résumé
BACKGROUND
BACKGROUND
Atherosclerosis, a leading cause of mortality, necessitates effective management of hypercholesterolemia, specifically elevated low-density lipoprotein cholesterol (LDL-C). The emergence of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has revolutionised lipid-lowering. PCSK9i demonstrates substantial LDL-C reduction and cardiovascular benefits, particularly in statin-intolerant or nonresponsive individuals. However, the potential pleiotropic effects of PCSK9i, especially on arterial stiffness, remain a subject of investigation. This systematic review and meta-analysis seek to provide a nuanced understanding of the potential pleiotropic effects of PCSK9i, specifically on arterial health. The primary objective was to analyse the influence of PCSK9i on arterial stiffness, extending beyond traditional lipid-lowering metrics and contributing to a more comprehensive approach to cardiovascular risk reduction.
METHODS
METHODS
A systematic search was conducted across major databases, clinical trial registries and grey literature. Inclusion criteria comprised adults in prospective cohort studies undergoing PCSK9i augmentation in lipid-lowering therapy, with a focus on arterial stiffness measured by pulse wave velocity (PWv). Random-effects meta-analyses, sensitivity analyses and meta-regression models were employed to assess the pooled effect of adding PCSK9i to lipid-lowering interventions on arterial stiffness.
RESULTS
RESULTS
Five studies (158 participants) met the inclusion criteria, demonstrating a significant reduction in PWv (mean difference: -2.61 m/s [95% CI: -3.70, -1.52]; ES: -1.62 [95% CI: -2.53, -.71]) upon adding PCSK9i to lipid-lowering interventions. Subgroup analysis and meta-regression models suggested potential sex-based and baseline PWv-dependent variations, emphasising patient-specific characteristics.
CONCLUSION
CONCLUSIONS
The meta-analysis provides robust evidence that adding PCSK9i to lipid-lowering interventions significantly improves arterial stiffness, indicating broader vascular benefits beyond LDL-C reduction.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14269Subventions
Organisme : European Regional Development Fund
ID : 2023-GRIN-34459
Informations de copyright
© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Wójcik C. Emerging lipid lowering agents targeting LDL cholesterol. Postgrad Med. 2020;132(5):433‐440.
Silverman MG, Ference BA, Im K, et al. Association between lowering LDL‐C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta‐analysis. JAMA. 2016;316(12):1289‐1297.
Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229‐243.
Kurobe H, Aihara K, Higashida M, et al. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J Atheroscler Thromb. 2011;18(12):1080‐1089.
Miyashita Y, Endo K, Saiki A, et al. Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio‐ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2010;17(10):1070‐1076.
Cesaro A, Bianconi V, Gragnano F, et al. Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition. Biofactors. 2020;46(3):367‐380.
Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283(4):2363‐2372.
Ruuth M, Nguyen SD, Vihervaara T, et al. Susceptibility of low‐density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur Heart J. 2018;39(27):2562‐2573.
Zhang Y, Zhang D, Liu X, et al. A practical statin recommendation system based on real‐world data to improve LDL‐C management in secondary prevention. J Cardiovasc Pharmacol. 2023;81(5):373‐380.
Burnap SA, Joshi A, Tsimikas S, et al. High‐density lipoproteins are the Main carriers of PCSK9 in the circulation. J Am Coll Cardiol. 2020;75(12):1495‐1497.
Kockx M, Kritharides L. Pancreatic PCSK9 and its involvement in diabetes. J Thorac Dis. 2019;11(Suppl 15):S2018‐S2022.
Huang YT, Ho LT, Hsu HY, Tu YK, Chien KL. Efficacy and safety of proprotein convertase subtilisin/Kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network meta‐analysis. Front Pharmacol. 2022;13:832614.
Mach F, Baigent C, Catapano AL, et al. Wiklund O; ESC scientific document group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111‐188.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227‐3337.
Singh M, McEvoy JW, Khan SU, et al. Comparison of transatlantic approaches to lipid management: the AHA/ACC/multisociety guidelines vs the ESC/EAS guidelines. Mayo Clin Proc. 2020;95(5):998‐1014.
Roberts WC. Two more drugs for dyslipidemia. Am J Cardiol. 2004;93(6):809‐811.
Gallego‐Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid‐lowering therapy. Eur J Pharmacol. 2020;878:173114.
Karagiannis AD, Liu M, Toth PP, et al. Pleiotropic anti‐atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation. Curr Atheroscler Rep. 2018;20(4):20.
Wang N, Woodward M, Huffman MD, Rodgers A. Compounding benefits of cholesterol‐lowering therapy for the reduction of major cardiovascular events: systematic review and meta‐analysis. Circ Cardiovasc Qual Outcomes. 2022;15(6):e008552.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. John Wiley and Sons; 2008:1‐649.
Study Quality Assessment Tools | NHLBI, NIH. https://www.nhlbi.nih.gov/health‐topics/study‐quality‐assessment‐tools
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Control Clin Trials. 1986;7(3):177‐188.
Jackson D, Turner R. Power analysis for random‐effects meta‐analysis. Res Synth Methods. 2017;8:290‐302.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Stat Med. 2002;21(11):1539‐1558.
Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta‐analysis. BMJ. 2001;323(7304):101‐105.
Scicali R, Russo GI, Di Mauro M, et al. Analysis of arterial stiffness and sexual function after adding on PCSK9 inhibitor treatment in male patients with familial hypercholesterolemia: a single lipid center real‐world experience. J Clin Med. 2020;9(11):3597.
Di Minno MND, Gentile M, Di Minno A, et al. Changes in carotid stiffness in patients with familial hypercholesterolemia treated with Evolocumab®: a prospective cohort study. Nutr Metab Cardiovasc Dis. 2020;30(6):996‐1004.
Mandraffino G, Scicali R, Rodríguez‐Carrio J, et al. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high‐intensity statins in patients with familial hypercholesterolemia: a two‐lipid center real‐world experience. J Clin Lipidol. 2020;14:231‐240.
Schremmer J, Busch L, Baasen S, et al. Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function. Microvasc Res. 2023;148:104513.
Silla A, Fogacci F, Punzo A, et al. Treatment with PCSK9 inhibitor Evolocumab improves vascular oxidative stress and arterial stiffness in hypercholesterolemic patients with high cardiovascular risk. Antioxidants (Basel). 2023;12(3):578.
Toscano A, Cinquegrani M, Scuruchi M, et al. PCSK9 plasma levels are associated with mechanical vascular impairment in familial hypercholesterolemia subjects without a history of atherosclerotic cardiovascular disease: results of six‐month add‐on PCSK9 inhibitor therapy. Biomol Ther. 2022;12(4):562.
Itzhaki Ben Zadok O, Mager A, Leshem‐Lev D, Lev E, Kornowski R, Eisen A. The effect of proprotein convertase subtilisin Kexin type 9 inhibitors on circulating endothelial progenitor cells in patients with cardiovascular disease. Cardiovasc Drugs Ther. 2022;36(1):85‐92.
Xiang Q, Liu WF, Zeng JL, et al. Effect of PCSK9 on vascular smooth muscle cell functions: a new player in atherosclerosis. Curr Med Chem. 2021;28(36):7446‐7460.
Leucker TM, Gerstenblith G, Schär M, et al. Evolocumab, a PCSK9‐monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia. J Am Heart Assoc. 2020;9(14):e016263.
Naegele M, Raemy Y, Barthelmes J, et al. Improvement of retinal microvascular function after initiation of lipid‐lowering therapy with PCSK9 inhibitors—an observational study. Eur Heart J. 2021;42:ehab724.3363.
Palombo C, Kozakova M. Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications. Vasc Pharmacol. 2016;77:1‐7.
Du H, Li X, Su N, et al. Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta‐analysis. Heart. 2019;105(15):1149‐1159.
Wang W, Feng Z, Bai J. Effects of alirocumab on cardiovascular events and all‐cause mortality: a systematic review and meta‐analysis. Rev Cardiovasc Med. 2021;22(3):873‐881.
Schmidt AF, Carter JL, Pearce LS, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;10:CD011748.
Cavero‐Redondo I, Deeks JJ, Alvarez‐Bueno C, et al. Comparative effect of physical exercise versus statins on improving arterial stiffness in patients with high cardiometabolic risk: a network meta‐analysis. PLoS Med. 2021;18(2):e1003543.
Cavero‐Redondo I, Saz‐Lara A, Lugones‐Sánchez C, et al. Comparative effect of antihypertensive drugs in improving arterial stiffness in adults with hypertension (RIGIPREV study). A network meta‐analysis. Front Pharmacol. 2023;14:1225795.
Saz‐Lara A, Cavero‐Redondo I, Álvarez‐Bueno C, et al. What type of physical exercise should be recommended for improving arterial stiffness on adult population? A network meta‐analysis. Eur J Cardiovasc Nurs. 2021;20(7):696‐716.
Saz‐Lara A, Cavero‐Redondo I, Martínez‐Vizcaíno V, Martínez‐Ortega IA, Notario‐Pacheco B, Pascual‐Morena C. The comparative effects of different types of Oral vitamin supplements on arterial stiffness: a network meta‐analysis. Nutrients. 2022;14(5):1009.
Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932‐943.
Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40(3):180‐196.
Mourouzis K, Siasos G, Oikonomou E, et al. Lipoprotein‐associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease. Lipids Health Dis. 2021;20(1):12.
Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all‐cause mortality with arterial stiffness: a systematic review and meta‐analysis. J Am Coll Cardiol. 2010;55(13):1318‐1327.
Sequí‐Domínguez I, Cavero‐Redondo I, Álvarez‐Bueno C, Pozuelo‐Carrascosa DP, Nuñez de Arenas‐Arroyo S, Martínez‐Vizcaíno V. Accuracy of pulse wave velocity predicting cardiovascular and all‐cause mortality. A systematic review and meta‐analysis. J Clin Med. 2020;9(7):2080.
Ben‐Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta‐analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63(7):636‐646.
Davies JM, Bailey MA, Griffin KJ, Scott DJ. Pulse wave velocity and the non‐invasive methods used to assess it: Complior, SphygmoCor, Arteriograph and Vicorder. Vascular. 2012;20(6):342‐349.
Boutouyrie P, Lacolley P, Briet M, et al. Pharmacological modulation of arterial stiffness. Drugs. 2011;71(13):1689‐1701.